



## Work Plan and Timeline 2020-24

The following work plan and timeline covers key milestones for the 2020 to 2024 period, focusing on two important aspects of the work: Insurance Capital Standard (ICS) monitoring and the comparability assessment for the Aggregation Method (AM).

As part of ICS monitoring, there will be annual confidential reporting of the reference ICS (and additional reporting, at the option of the group-wide supervisor). The annual cycle during the monitoring period will be very similar to the process followed during field testing with confidential reporting launched annually in mid-Quarter 2 and data due in late Quarter 3. Supervisory college discussions should begin after group-wide supervisors (GWSs) and the IAIS have had an opportunity to review the data submission, but in time to be considered in the annual process ahead of the next year of confidential reporting. As part of the annual ICS monitoring, the IAIS will discuss:

- the results of the analysis and feedback received on the reference ICS; and
- the additional reporting (ie GAAP Plus and other methods of calculation of the ICS capital requirement, including internal models, relative to the reference ICS).

In support of the work on comparability assessment, there will be an annual AM data collection. The timing of this data collection will be similar to that for the ICS confidential reporting.

The IAIS will also have regular review points to monitor participation by Internationally Active Insurance Groups (IAIGs) in the monitoring period.

In addition to this, there will be specific activities related to:

- Public consultation on the ICS as a prescribed capital requirement (PCR) including consultation on GAAP Plus, criteria for other methods of calculation of the ICS capital requirement and treatment of NAIC Designations (as part of standard method or other methods)
- An economic impact assessment on ICS prior to it being adopted as a PCR
- Public consultations on the definition, high-level principles and criteria to assess whether an AM provides comparable outcomes to the ICS
- An assessment of whether the AM provides comparable outcomes to the ICS.

Key milestones with respect to these activities and other relevant milestones during the 2020 to 2024 period are outlined below:

Date	ICS Monitoring	Comparability Assessment
2020, Q1	<p><b>January:</b> Updated Declaration of Consent to be signed by all IAIGs participating in the monitoring period</p> <p>IAIS sends a letter on participation in the monitoring period to GWSs, asking them to convey the message to their IAIG(s) in an appropriate form</p> <p>Review point for IAIG participation</p>	<p>Based on the high level definition and overarching approach, the IAIS continues discussions on developing the high level principles to inform the criteria that will be used to assess whether an AM provides comparable outcomes to the ICS</p> <p>Review point for IAIG participation</p>
2020, Q3	<p><b>Early-July:</b> IAIS publishes register of IAIGs that have been publicly disclosed by GWSs</p>	<p><b>Early-July:</b> Issue a consultation on the draft definition of comparable outcomes and the high-level principles to inform the criteria that will be used to assess whether an AM provides comparable outcomes to the ICS</p>
2021, Q1	Review point for IAIG participation	Review point for IAIG participation
2021, Q4		Issue a consultation on draft criteria to assess whether an AM provides comparable outcomes to the ICS
2022, Q1	Review point for IAIG participation	Review point for IAIG participation
2022, Q4		Adoption at the AGM of the definition, high level principles and criteria to assess whether an AM provides comparable outcomes to the ICS.
2023, Q1	Review point for IAIG participation	Review point for IAIG participation
2023, Q3	<p>Issue a consultation package on ICS as a PCR, including consultation on GAAP Plus, criteria for other methods of calculation of the ICS capital requirement and treatment of NAIC Designations (as part of standard method or other methods)</p> <p>Economic impact assessment begins</p>	Assessment of whether the AM provides comparable outcomes to the ICS begins
2024, Q1	Review point for IAIG participation	Review point for IAIG participation
2024, Q2	Economic impact assessment ends	Assessment of whether the AM provides comparable outcomes to the ICS ends
2024, Q3	Decision on ICS as a PCR, including decisions on the inclusion of GAAP Plus and other methods of calculation	Decision on whether the AM provides comparable outcomes to the ICS

Date	ICS Monitoring	Comparability Assessment
	<p>of the ICS capital requirement in the ICS and the treatment of NAIC Designations (as part of the standard method or other methods)</p> <p>Publication of a report on the outcome of the economic impact assessment.</p>	<p>Publication of a report on the outcome of the assessment of whether the AM provides comparable outcomes to the ICS</p>
<b>2024, Q4</b>	Adoption of ICS as a PCR	